These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 36878533)

  • 1. Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: case report and systematic review of the literature.
    Liu LL; Skribek M; Harmenberg U; Gerling M
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36878533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports.
    Noseda R; Bertoli R; Müller L; Ceschi A
    J Immunother Cancer; 2019 May; 7(1):117. PubMed ID: 31046841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemophagocytic Lymphohistiocytosis Secondary to Immune Checkpoint Inhibitor Therapy.
    Rajapakse P; Andanamala H
    World J Oncol; 2022 Apr; 13(2):49-52. PubMed ID: 35571340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemophagocytic lymphohistiocytosis (HLH) and cytokine release syndrome (CRS) in a patient with oncogene-addicted metastatic non-small cell lung cancer (NSCLC) following combination chemotherapy-immunotherapy.
    Heynemann S; Vanguru V; Adelstein S; Kao S
    Asia Pac J Clin Oncol; 2024 Apr; 20(2):315-318. PubMed ID: 36562695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Checkpoint Inhibitor-Related Cytokine Release Syndrome: Analysis of WHO Global Pharmacovigilance Database.
    Ceschi A; Noseda R; Palin K; Verhamme K
    Front Pharmacol; 2020; 11():557. PubMed ID: 32425791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine Release Syndrome in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Case Series of 25 Patients and Review of the Literature.
    Tay SH; Toh MMX; Thian YL; Vellayappan BA; Fairhurst AM; Chan YH; Aminkeng F; Bharwani LD; Huang Y; Mak A; Wong ASC
    Front Immunol; 2022; 13():807050. PubMed ID: 35154124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute kidney injury associated with immune checkpoint inhibitors: A pharmacovigilance study.
    Zhu J; Wu J; Chen P; You K; Su J; Gao Z; Bi Z; Feng M
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109350. PubMed ID: 36272360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitor use: A review of the current knowledge and future directions.
    Walmsley CS; Schoepflin Z; De Brabandt C; Rangachari D; Berwick S; Patell R
    Blood Cells Mol Dis; 2025 Feb; 110():102896. PubMed ID: 39366077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: a case report and systematic review.
    Zhai C; Jin X; You L; Yan N; Dong J; Qiao S; Zhong Y; Zheng Y; Pan H
    BMC Geriatr; 2024 Jan; 24(1):32. PubMed ID: 38191289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy.
    Dimitriou F; Hogan S; Menzies AM; Dummer R; Long GV
    Eur J Cancer; 2021 Nov; 157():214-224. PubMed ID: 34536945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
    J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemophagocytic lymphohistiocytosis in two patients following treatment with pembrolizumab: two case reports and a literature review.
    Wei Y; He W; Sun W; Wu C; Ren D; Wang X; Zhang M; Huang M; Ji N
    Transl Cancer Res; 2022 Aug; 11(8):2960-2966. PubMed ID: 36093533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characterization of hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors: a review of published cases.
    Xu Z; Li H; Yu X; Luo J; Zhang Z
    Hematology; 2024 Dec; 29(1):2340144. PubMed ID: 38606818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
    Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
    Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokine release syndrome after treatment with immune checkpoint inhibitors: an observational cohort study of 2672 patients from Karolinska University Hospital in Sweden.
    Hamida O; Karlsson F; Lundqvist A; Gerling M; Liu LL
    Oncoimmunology; 2024; 13(1):2372875. PubMed ID: 38974986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.
    Mikami T; Liaw B; Asada M; Niimura T; Zamami Y; Green-LaRoche D; Pai L; Levy M; Jeyapalan S
    J Neurooncol; 2021 Mar; 152(1):135-144. PubMed ID: 33423151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance.
    Mascolo A; Scavone C; Ferrajolo C; Rafaniello C; Danesi R; Del Re M; Russo A; Coscioni E; Rossi F; Alfano R; Capuano A
    Drug Saf; 2021 Sep; 44(9):957-971. PubMed ID: 34145536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review.
    Velasco R; Villagrán M; Jové M; Simó M; Vilariño N; Alemany M; Palmero R; Martínez-Villacampa MM; Nadal E; Bruna J
    JAMA Neurol; 2021 Jul; 78(7):864-873. PubMed ID: 33720308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemophagocytic Lymphohistiocytosis Associated with Immunological Checkpoint Inhibitors: A Pharmacovigilance Study.
    Diaz L; Jauzelon B; Dillies AC; Le Souder C; Faillie JL; Maria ATJ; Palassin P
    J Clin Med; 2023 Mar; 12(5):. PubMed ID: 36902771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database.
    Anquetil C; Salem JE; Lebrun-Vignes B; Touhami S; Desbois AC; Maalouf G; Domont F; Allenbach Y; Cacoub P; Bodaghi B; Saadoun D
    J Autoimmun; 2020 Jul; 111():102454. PubMed ID: 32303423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.